---
title: 'Executive Director, Statistical Programming at 4D Molecular Therapeutics'
canonical: 'https://feeny.ai/job/executive-director-statistical-programming-4d-molecular-therapeutics-united-sbx771erzng7'
type: 'job'
last_seen: '2026-10-18'
---

# Executive Director, Statistical Programming at 4D Molecular Therapeutics

- **Company:** 4D Molecular Therapeutics
- **Location:** United States
- **Work type:** remote
- **Posted:** 2026-09-23
- **Last confirmed live:** 2026-10-18
- **Apply:** https://4dmoleculartherapeutics.com/careers/?gh_jid=4736462005

## Job description

Attention recruitment agencies: All agency inquiries are vetted through 4DMT’s internal Talent Acquisition team. No unsolicited resumes will be accepted. The 4DMT Talent Acquisition team must expressly engage agencies on any requisition. Agencies contacting hiring managers directly will not be tolerated, and doing so may impact your ability to work with 4DMT in the future.

4DMT is a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients. The Company’s lead product candidate 4D-150 is designed to be a backbone therapy forming the foundation of treatment of blinding retinal vascular diseases by providing multi-year sustained delivery of anti-VEGF (aflibercept and anti-VEGF-C) with a single, safe, intravitreal injection, which substantially reduces the treatment burden associated with current bolus injections. The Company’s lead indication for 4D-150 is wet age-related macular degeneration, which is currently in Phase 3 development, and second indication is diabetic macular edema. The Company’s second product candidate is 4D-710, which is the first known genetic medicine to demonstrate successful delivery and expression of the CFTR transgene in the lungs of people with cystic fibrosis after aerosol delivery

## GENERAL SUMMARY:

The Executive Director of Statistical Programming will provide strategic and operational leadership for statistical programming across assigned development programs. The role will apply deep programming expertise to guide in-house deliverables, ensure rigorous quality review of outsourced statistical deliverables, and establish scalable standards and processes. They will serve as a senior member of cross-functional teams, partnering with Biostatistics, Data Management, Clinical Development, Regulatory, Clinical Operations, Quality, IT, and external vendors to plan, prioritize, and execute activities supporting program and organizational objectives.

## MAJOR DUTIES & RESPONSIBILITIES:

- Provide strategic and operational statistical programming leadership for assigned indications and development programs that may consist of multiple clinical trials and submission deliverables
- Partner closely with biostatisticians and cross-functional stakeholders to review statistical analysis plans and ensure development of clear, fit-for-purpose data and analysis programming specifications
- Ensure complete, auditable, and inspection-ready programming documentation for clinical trial analyses and regulatory submissions
- Lead the development, governance, documentation, and maintenance of reusable programming code, standards, templates, and best practices
- Partner with IT and functional leadership to define and maintain fit-for-purpose statistical computing infrastructure, including the SAS server environment and related tools
- Provide senior statistical programming expertise and, as needed, biometrics leadership on select projects and cross-functional initiatives
- Collaborate with various functions to ensure robust CRF/EDC development, and quality data collection for the assigned clinical trials
- Oversee biometrics vendors and external programming partners to ensure timely, high-quality statistical deliverables, effective issue escalation, and clear accountability
- Ensure quality review of outsourced statistical deliverables, including in-house double programming or quality control as needed, and coordinate internal review comments and resolution
- Lead or contribute to the development of function-level standards, SOPs, work instructions, templates, and continuous improvement initiatives
- Stay abreast of industry developments in biostatistics, statistical programming, regulatory expectations, automation, and data standards, and apply relevant advancements to systems and processes
- Establish programming strategy, resource priorities, quality expectations, and risk mitigation plans, and communicate key decisions and escalations to senior stakeholders
- Other duties as assigned, nothing in this job description restricts management’s right to assign or reassign duties and responsibilities to this job at any time.

## QUALIFICATIONS:

Education:

- A./B.S. degree in statistics, computer science, or other quantitative science major required
- Advanced degree (M.A./M.S.) preferred, or equivalent experience

Experience:

- 17+ years of relevant statistical programming, biometrics, or clinical development experience, including significant leadership experience in clinical development and regulatory submissions
- Demonstrated experience leading statistical programming strategy and execution for regulatory submissions, including BLA/IND or equivalent global health authority submissions
- 8+ years of management experience, including scale-up of in-house programming team
- Experience in ophthalmology and/or biologic/gene therapy a plus

Other Qualifications/Skills:

- Expert SAS programming skills required, with proficiency in SAS/BASE, SAS Macros, SAS/STAT, and ODS; proficiency in SAS/SQL, SAS/GRAPH, or SAS/ACCESS is a plus
- Proficiency in R programming a plus
- Proficiency in Microsoft Office Apps, such as WORD, EXCEL, and PowerPoint (familiar with the “Chart” features in EXCEL/PowerPoint a plus)
- Strong understanding of standards specific to clinical trials, including CDISC, SDTM, ADaM, CDASH, MedDRA, and WHODrug
- Experience with all clinical phases (I, II, III, and IV) is desirable
- Experience leading or overseeing BLA/IND submissions is strongly desirable
- Good understanding of regulatory requirements for submission-related activities (e.g., CDISC, CDASH, eCTD) and CRT packages (e.g., XPTs Define/xml, reviewer’s guide, analysis metadata report, executable programs) is desirable
- Able to run the P21 checks is a plus
- Knowledge of applicable GCP/FDACHMP//ICH/HIPPA regulations
- Displays excellent organization, prioritization, and time management skills, with strong attention to detail and the ability to lead multiple complex priorities in a fast-paced environment with shifting timelines and competing demands
- Excellent written and verbal communication skills, with the ability to influence senior stakeholders and communicate complex technical information clearly across functions
- Proven conceptual, analytical, strategic, and enterprise-level thinking
- Strong interpersonal, vendor oversight, people leadership, and project management skills
- Proactively identifies risks, issues, and possible solutions, and drives timely decision-making, escalation, and resolution

Travel: <5%

Physical Requirements and Working Conditions:

- Physical Activity - Repetitive motions: Making substantial movements (motions) of the wrists, hands, and/or fingers. Fingering: Picking, pinching, typing or otherwise working, primarily with fingers rather than with whole hand or arm as in handling. Talking: Expressing or exchanging ideas by means of the spoken word.
- Physical Requirements - Sedentary work: Exerting up to 10 pounds of force occasionally and/or a negligible amount of force frequently or constantly to lift, carry, push, pull or otherwise move objects, including the human body. Sedentary work involves sitting most of the time. Jobs are sedentary if walking and standing are required only occasionally and all other sedentary criteria are met.
- Working Conditions - The worker is not substantially exposed to adverse environmental conditions (as in typical office or administrative work).

Base salary compensation range: $298,000 - $340,000

Please note, the base salary compensation range and actual salary offered to the final candidate depends on various factors: candidate’s geographical location, relevant work experience, skills, and years of experience. 4DMT provides equal employment opportunities to all employees and applicants for employment without regard to race, color, religion, gender, sexual orientation, national origin, age, disability, genetic information, marital status, status as a covered veteran, and any other category protected under applicable federal, state, provincial and local laws.

Equal Opportunity Employer/Protected Veterans/Individuals with Disabilities

## About 4D Molecular Therapeutics

## Company Overview
- **One-liner**: 4D Molecular Therapeutics is a late-stage clinical biotechnology company inventing and developing customized genetic medicines using a proprietary vector evolution platform to treat large-market diseases.
- **Entity Type**: Public (NASDAQ: FDMT)
- **Headquarters**: Emeryville, California, United States
- **Founded**: 2013
- **Founders**: David Kirn, MD (Co-Founder, President, and CEO)

## Core Business
- **Primary industry**: Biotechnology / Genetic Medicine / Gene Therapy
- **Target customers**: B2B (partnerships with other biopharma companies) and B2C (patients with retinal and pulmonary diseases)
- **Mission or purpose statement**: "To unlock the full potential of genetic medicines for large market diseases" by harnessing directed evolution to invent customized and enhanced vectors for transformative products.

## Products & Services
- **4D-150**: A clinical-stage genetic medicine candidate for retinal vascular diseases (wet age-related macular degeneration and diabetic macular edema). It is designed as a single, routine, low-dose intravitreal injection that provides multi-year sustained delivery of anti-VEGF (aflibercept and anti-VEGF-C). Currently in Phase 3 clinical trials (4FRONT-1 and 4FRONT-2) for wet AMD and Phase 1/2 for DME.
- **4D-710**: An investigational genetic medicine candidate for cystic fibrosis lung disease. It uses the A101 vector for aerosol delivery of a corrective CFTR transgene (CFTR∆R) and is designed for patients ineligible for or who have discontinued CFTR modulator therapy. Currently in Phase 1/2.
- **4D-175**: A preclinical candidate for geographic atrophy (a form of dry AMD) using the R100 vector to deliver a shortened form of human complement factor H (sCFH) to restore normal complement regulation.
- **4D-725**: A preclinical candidate for alpha-1 antitrypsin (A1AT) lung disease using the A101 vector for aerosol delivery.

## Market Standing
- **Valuation/Market Cap**: $756.4 million (as of latest data from LinkedIn)
- **Key Metric**: Annual Revenue of $85.2 million (as of latest data from LinkedIn)
- **Notable Investors/Partners**: The company is publicly traded (IPO in 2020). Key partnerships are sought for pipeline candidates like 4D-175 and 4D-725.
- **Growth Signals**: The company is a late-stage biotech with two Phase 3 trials (4FRONT-1 and 4FRONT-2) for its lead candidate 4D-150 in wet AMD, and a Phase 1/2 trial for 4D-710 in cystic fibrosis. The company has a presence in Ecuador, France, and India. LinkedIn followers grew 24.7% year-over-year.

## Competitive Advantages
- **Proprietary Vector Platform (Therapeutic Vector Evolution)**: The company uses directed evolution to create customized and proprietary AAV vectors (e.g., R100 for retina, A101 for lung) that are optimized for specific tissues and routes of administration, which is a significant differentiator from standard gene therapy approaches.
- **Large-Market Focus**: Unlike many gene therapy companies targeting ultra-rare diseases, 4DMT is focused on large-market indications (wet AMD, DME, cystic fibrosis) with high unmet need, offering a potentially massive commercial opportunity.
- **Durable, Single-Dose Therapies**: Their products are designed to provide multi-year efficacy from a single injection, which could dramatically reduce treatment burden for patients compared to current standard-of-care (e.g., frequent eye injections for wet AMD).

## Strategic Focus
- **Advancing Late-Stage Pipeline**: The primary focus is executing the Phase 3 programs for 4D-150 in wet AMD and progressing 4D-710 in cystic fibrosis.
- **Expanding Indications**: The company is exploring 4D-150 for diabetic macular edema (DME) and seeking partnerships to advance 4D-175 (geographic atrophy) and 4D-725 (A1AT deficiency).
- **Platform Expansion**: Continuing to leverage the Therapeutic Vector Evolution platform to develop new genetic medicines for other large-market diseases.

## Why Work Here
- **Mission-Driven Culture**: The company is deeply committed to "daring to cure" and unlocking the potential of genetic medicine for patients with devastating diseases. Core values include "Dare to Cure," "Break Boundaries," "Prepare & Execute Relentlessly," and "Beyond Yourself."
- **Innovative Science**: Employees work on cutting-edge science at the intersection of gene therapy, vector engineering, and clinical development, tackling some of the biggest challenges in medicine.
- **Collaborative Environment**: The company emphasizes teamwork, internal and external collaboration, and a culture that empowers innovation.
- **Location & Perks**: Based in Emeryville, CA (San Francisco Bay Area). The company offers a competitive benefits package and a dynamic, collaborative environment.
- **Diversity & Inclusion**: 4DMT champions diversity, equity, and inclusion through an employee-led initiative called "4Diversity," which partners with charitable organizations and focuses on social equity.
- **Work Authorization**: Candidates must be authorized to work in the U.S. The company does not sponsor new nonimmigrant visa status petitions but welcomes candidates who require transfers or extensions.

## Sources
1. [4dmoleculartherapeutics.com](https://4dmoleculartherapeutics.com/)
2. [4dmoleculartherapeutics.com - About](https://4dmoleculartherapeutics.com/about/)
3. [4dmoleculartherapeutics.com - Careers](https://4dmoleculartherapeutics.com/careers/)
4. [4dmoleculartherapeutics.com - Pipeline](https://4dmoleculartherapeutics.com/pipeline/)
5. [LinkedIn - 4D Molecular Therapeutics](https://www.linkedin.com/company/4d-molecular-therapeutics-llc)

## Other roles at 4D Molecular Therapeutics

- [Senior Accountant](https://feeny.ai/job/senior-accountant-4d-molecular-therapeutics-emeryville-vh8ys1p9tr78) — Emeryville, CA
- [Vice President, Biostatistics](https://feeny.ai/job/vice-president-biostatistics-4d-molecular-therapeutics-united-states-qwkv5jtj92h3) — United States
- [Senior Director, Clinical Quality  Assurance (CQA)](https://feeny.ai/job/senior-director-clinical-quality-assurance-cqa-4d-molecular-therapeutics-united-xhe4n9jrfe00) — United States
- [Sr. QA Computer System Validation Mgr.](https://feeny.ai/job/sr-qa-computer-system-validation-mgr-4d-molecular-therapeutics-united-states-aq7bmg1j30ra) — United States
- [Director, Corporate Counsel](https://feeny.ai/job/director-corporate-counsel-4d-molecular-therapeutics-united-states-tqb6yhgnqdae) — United States
- [Senior Director, IT Compliance & Governance (Contract)](https://feeny.ai/job/senior-director-it-compliance-governance-contract-4d-molecular-therapeutics-p4334wpdrvzd) — United States
- [Senior Business Systems Architect](https://feeny.ai/job/senior-business-systems-architect-4d-molecular-therapeutics-united-states-0jycx224r9tk) — United States
- [Vice President, Clinical Development](https://feeny.ai/job/vice-president-clinical-development-4d-molecular-therapeutics-united-states-8zdnvfs5n4ha) — United States
- [Executive Medical Director (Retina Program)](https://feeny.ai/job/executive-medical-director-retina-program-4d-molecular-therapeutics-united-kr1mkby7m4kt) — United States